Indo US Bio-Tech Q1 Results Revenue ₹26,044.45 Lakhs Profit (Before Tax) ₹10,780.06 Lakhs

Indo US Bio-Tech Q1 Results 

Indo US Bio-Tech reported its financial performance with a mix of gains and challenges for the first quarter ended 30 June 2024, . The company saw a significant increase in revenue compared to the previous year. This rise was driven by higher sales in their biotech products and a boost in interest income. 

Revenue from operations reached ₹20,944.79 lakhs, up from ₹15,156.54 lakhs in the same quarter last year. The total revenue, including other income, was ₹26,044.45 lakhs, reflecting strong performance.

Expenses also grew during this period. Finance costs increased to ₹7,663.79 lakhs, and employee benefits expenses rose to ₹5,290.26 lakhs. Other expenses, including impairment on financial instruments and depreciation, added to the total expenses of ₹15,264.39 lakhs. Despite these higher costs, the company's profit before tax improved significantly to ₹10,780.06 lakhs from ₹6,074.42 lakhs last year. 

For the first quarter ended 30 June 2024 after accounting for taxes, the profit for the period stood at ₹8,332.99 lakhs. Their total comprehensive income, which includes other comprehensive income, was ₹8,325.97 lakhs, showing overall positive results for the quarter.

Source: Here 

For More Q1 Results check our Twitter Page 

Indo US Bio-Tech Q1 Results 2024-2025 Overview

Indo US Bio-Tech posted solid financial results for the first quarter of the fiscal year 2024-2025, . The company's revenue from operations saw a notable increase, reaching ₹20,944.79 lakhs, compared to ₹15,156.54 lakhs in the previous year. 

Here is the information:

Indo US Bio-Tech Financial Summary

Indo US Bio-Tech is a company listed on the stock market. Its market capitalization is ₹553 Crore, and the current price of its stock is ₹276. The stock has reached a high of ₹304 and a low of ₹180 in recent trading. 

Here's the financial data:

Quarterly Results

The Indo US Bio-Tech financial performance for three periods: Dec 2023, Mar 2024, and Jun 2024. In Dec 2023, the company had sales of 22.11, which increased to 37.88 in Mar 2024 but fell to 24.72 in Jun 2024. Expenses also rose from 17.88 to 32.67 and then slightly decreased to 21.03. 

Here's a summary of the financial data:

About Indo US Bio-Tech 

Indo US Bio-Tech is a company dedicated to advancing agriculture through innovative research and high-quality products. They focus on using modern technology to ensure that all their products, including seeds and laboratory testing services, meet strict standards of quality and purity. 

Indo US Bio-Tech’s main goal is to develop a range of seeds that can grow well in different climates and environments. These seeds are designed to be resistant to various challenges such as extreme temperatures, humidity, and diseases, which helps farmers improve their yields and manage their crops better.

Indo US Bio-Tech is working towards achieving ISO 9001:2008 certification, which is a global standard for quality management. This certification will help Indo US Bio-Tech maintain and enhance its quality standards. 

Indo US Bio-Tech is a registered member of the National Seed Association of India, which shows their commitment to the agricultural industry in India. By focusing on these areas, Indo US Bio-Tech aims to make a positive impact on agriculture and support farmers with reliable and effective solutions.